Biostar Pharmaceuticals, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues

Biostar Pharmaceuticals, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues

Biostar Pharmaceuticals, Inc. reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues of $623.38 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-04-13.

Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation

us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues · last filed 2017-04-13

• Biostar Pharmaceuticals, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, issues for fiscal 2016 was $623.38K.